[Non-infectious systemic diseases and uveitis]. / Enfermedades sistémicas no infecciosas y uveítis.

Uveitis can be defined as any inflammation affecting the uveal tract, although in clinical practice this term includes any intraocular inflammatory event. The etiology of this inflammation can be related to an endogenous mechanism in the clinical course of a systemic disease (sarcoidosis, Behçet's disease, multiple sclerosis, Vogt-Koyanagi-Harada disease, etc.), or an isolated ocular entity. Sometimes, ocular inflammation is the initial manifestation of an undiagnosed systemic disease. On the other hand, ocular involvement could be the main cause of morbidity of the disease, and early diagnosis and treatment is an important issue in order to avoid irreversible ocular damage. In this article, the authors review some relevant clinical, diagnostic and therapeutic topics related to the most common non-infectious systemic diseases associated with uveitis.

The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative.

PURPOSE: With uveitis being one of the leading causes of blindness worldwide, biological therapies have arisen as an option for the treatment of refractory cases based on good results shown in clinical practice. The goal of this study is to provide a systematic review of current knowledge of the role and possible uses of tocilizumab in the field of ophthalmology. MATERIALS AND METHODS: We performed a search for records reporting the use of tocilizumab for various diseases in MEDLINE (PubMed and OVID). We conducted an analysis of several individual studies and their reported individual patient data (82 eyes of 45 patients) published from 2011 to 2017. CONCLUSIONS: Tocilizumab may prove to be an effective choice for the treatment of a variety of ocular conditions such as refractory uveitis, inflammatory macular edema, vitreo-retinal tumors and thyroid orbitopathy, leading to control of the inflammation in these patients. Further studies need to be conducted to establish its safety and efficacy.

Ultrasound biomicroscopy of ZSAL-4 anterior chamber phakic intraocular lens for high myopia.

PURPOSE: To evaluate the intraocular location and anatomic relationship to other structures of the ZSAL-4 angle-supported anterior chamber phakic intraocular lens (IOL) for high myopia using ultrasound biomicroscopy (UBM). SETTING: Clínica de Nuestra Señora de la Concepción, Fundación Jiménez Díaz, and Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Madrid, Spain. METHODS: Eight phakic myopic eyes corrected by ZSAL-4 angle-supported anterior chamber phakic IOLs were examined by UBM. The distance between the corneal endothelium and the IOL at the central and peripheral cornea and between the phakic IOL and the iris was measured. RESULTS: The mean distance between the central cornea and the IOL was 2361.37 microm +/- 109.62 (SD); between the edge of the IOL optic and the endothelium, 1646.24 +/- 27.06 microm; and between the IOL and the iris, 354.46 +/- 41.61 microm. The IOL footplates appeared to be correctly positioned in the anterior chamber angle in all eyes. CONCLUSION: The space between the IOL and the endothelium was greater in eyes with the ZSAL-4 angle-supported phakic IOL than in eyes with other angle-supported phakic IOLs. The possibility of intermittent contact between the IOL edge and the midperipheral cornea plays a minor role in the mechanism of endothelial damage with this lens model.

Soft contact lens fitting after intrastromal corneal ring segment implantation to treat keratoconus.

PURPOSE: To assess the feasibility of fitting a lathed soft toric contact lens (STCL) after the implant of intrastromal corneal ring segments (ICRSs) to treat keratoconus. METHODS: Six months after ICRS implantation, 47 eyes of 47 patients (18-45 years) were fitted with a STCL. In each eye, we determined refractive error, uncorrected (UDVA) and corrected distance visual acuity (CDVA), and keratometry and asphericity measures. The outcome of STCL fitting was defined according to CDVA as successful (≤0.2logMAR) or unsuccessful (>0.2logMAR). Patients in the unsuccessful group were refitted with a piggy-back (PB) system. The above variables and the change in CDVA observed after STCL and PB lens fitting from spectacle CDVA were compared in the two groups. RESULTS: STCL fitting was successful in 75%, 66.66% and 0% of the ICRS implanted eyes with stages I-III keratoconus, respectively. Spectacle-CDVA was 1.5 lines better and mean corneal power was 3.62D lower in the successful STCL group. In this group, the difference in cylinder axis between spectacles and STCL was 24.25° lower. PB refitting achieved a PB-CDVA ≤0.2logMAR in all cases. A similar difference in the CDVA change achieved by contact lenses versus spectacles was observed in the successful STCL and PB refitted groups. CONCLUSION: STCL fitting is a feasible option in a large proportion of patients implanted with ICRS. When these lenses are unsatisfactory, a PB system is a good alternative.